c106482.htm - Prepared by Imprima

 

 

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549
 

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

April 24, 2012

________________

 

        NOVO NORDISK A/S        
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

 

 


 

 

Company Announcement

10 April 2012

Novo Nordisk A/S – Share repurchase programme

On 2 February 2012 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.5 billion in the period from 2 February 2012 to 25 April 2012.

Since the announcement as of 2 April 2012, the following transactions have been made under the programme:

 

Number of
shares

Average
purchase price

Transaction value,
DKK

Accumulated, last
announcement

2,376,000

 

1,856,008,774

2 April 2012

55,000

798.02

43,890,935

3 April 2012

55,000

839.98

46,198,972

4 April 2012

55,000

823.38

45,286,087

Accumulated under
the programme

2,541,000

 

1,991,384,768

With the transactions stated above, Novo Nordisk owns a total of 27,494,627 treasury shares, corresponding to 4.7% of the share capital. The total amount of shares in the company is 580,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares worth DKK 12.0 billion during a 12 month period beginning 2 February 2012. As of 4 April 2012, Novo Nordisk has repurchased a total of 2,541,000 B shares equal to a transaction value of DKK 1,991,384,768.

 

 

 

         

Company Announcement no 23 / 2012

Page 1 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 

 


 

 

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,700 employees in 75 countries, and markets its products in more than 190 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com

Further information:

 

 

Media:

Investors:

 

Anne Margrethe Hauge

Klaus Bülow Davidsen

Tel: (+45) 4442 3450

Tel: (+45) 4442 3176

amhg@novonordisk.com

klda@novonordisk.com

 

 

Frank Daniel Mersebach

 

Tel: (+45) 4442 0604

 

fdni@novonordisk.com

 

 

Lars Borup Jacobsen

 

Tel: (+45) 3075 3479

 

lbpj@novonordisk.com

In North America:

 

Ken Inchausti

Jannick Lindegaard

Tel: (+1) 609 514 8316

Tel: (+1) 609 786 4575

kiau@novonordisk.com

jlis@novonordisk.com

 

 

 

 

 

 

         

Company Announcement no 23 / 2012

Page 2 of 2

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Telefax:

+45 4444 6626

Internet:

novonordisk.com

CVR no:

24256790

 

 

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: April 24, 2012

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer